While it is common to hear that drug developers are in the early stages of integrating artificial intelligence with their drug research, discovery, and development efforts, one Bristol Myers Squibb (BMS) executive recently offered a more descriptive and no less accurate metaphor stretching back some 45 years.
“The state of artificial intelligence and machine learning is similar to where we were with personal computers in 1980,” Greg Meyers, BMS’ executive vice president and chief digital & technology officer, recently stated on the company’s technologies webpage. “Technology and digital capabilities will transform our ways of working, from how we develop medicines, to how we improve the patient…